Latest Industry Insights

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

Dr. Aaron Wenger tells us about SPRQ chemistry, highlighting its unique benefits and role in expanding our understanding of rare diseases.

Hear from an early user of the neofleXTM MALDI-TOF instrument about how the technology adds new capabilities to MSI workflows.

Cell and gene therapies are revolutionizing medicine. Looking to 2025, advancements in allogeneic therapies, streamlined autologous processes and broader applications promise increased accessibility and innovation in treating complex diseases.

Technology Networks spoke with Dr. Mohamed Alameri to explore how population-wide genome initiatives are addressing gaps in genomic data representation and advancing precision medicine in areas such as rare diseases and cancer.

Dr. Eric Kelsic, CEO and co-founder of Dyno Therapeutics, explains how AI could reduce the cost of gene therapy delivery to $0.

In this interview, we spoke to Jason Koth, product management lead at Scale Biosciences, to learn more about their new ScalePlex technology for leveraging and overcoming current limitations within single-cell genomics.

In this article, Michelle Fraser and Amanda Haupthow discuss how engineered nucleases in combination with next-generation base editing platforms are paving the way for the development of novel treatments for genetic disorders and diseases.

Elsevier’s “Insights 2024: Attitudes toward AI” report reveals how researchers feel about AI and what is needed to increase trust in these tools. Here, Mirit Eldor, managing director, life sciences at Elsevier discusses these findings further.